Guerbet — Earnings Release 2011

Apr 27, 2011

P RESS RELEASE

2011 first-quarter net sales

Villepinte, 27 April 2011

Consolidated Group revenue (IFRS):

In thousands of euros	2011	2010	Change
Total first quarter …………………………	95,053	86,684	+9.7%

Consolidated revenue by region:

In thousands of euros	2011	2010	Change
European subsidiaries	68,118	65,974	+3.2%
Other markets	26,936	20,709	+30.1%
Total……………………………………	95,053	86,684	+ 9.7%

First quarter revenue up 9.7%

Sales in Europe rose 3.2% driven by gains from Dotarem.

Other markets grew 30.1%, increasing their share in total Group revenue to 28%, up from 24% in 2010. In the US, the resumption of direct distribution of Lipiodol (Ethiodol) provided a strong and exceptional boost to first-quarter sales. In the rest of the world, both Dotarem and Xenetix showed strong growth.

Dotarem sales were up 19.7% on gains of 17.6% in Europe and 31.9% for other regions.

Xenetix sales increased 5.4% that included a 2.6% decline in Europe and 29.6% growth in other regions.

Contact: Finance and Administration Department Tel. 01 45 91 50 69